Nipro Corporation (NPRRF) Fair Value & Analysis

US · Market cap $1.6B

A solid business, but screening 61% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($4.86). The favourable scenario is already priced in.
• Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range ($2.48 to $4.86) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range $7.40 – $9.96 · fair‑value band $2.48 – $4.86 · the $9.96 price screens above the $3.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Nipro Corporation (NPRRF) currently trades at $9.96, while our model-based Fair Value estimate is $3.89, implying the stock looks roughly 60.9% overvalued today. The Quality Score stands at 50/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Nipro Corporation generated revenue of $484B at a net margin of 3.1%. Revenue grew 7.1% year over year. It earns a return on equity of 9.1%. Net debt stands at $498B. Fundamentals as of Jul 17, 2026

Our scenario range runs from $2.48 (bear case) to $4.86 (bull case); at $9.96, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 24% above its 52-week low, currently above its 200-day average.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models ($13.56) versus Earnings-Based ($1.82). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.

Full company description

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company's Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services. Its Pharma Packaging business offers glass products and other comprehensive pharmaceutical packaging, such as glass vials, ampoules, and syringes; tube glass; and other parts of pharmaceutical packaging, such as rubber plugs, as well as provides glass for thermos bottles, and lighting and containers. The company also offers business management services. It serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Nipro Corporation reported revenue of $645B in FY2025 versus $456B in FY2021, a compound +9.1%/yr. Reported net income was $5.1B in FY2025, compounding −22.5%/yr from FY2021.

Watch NPRRF: get an alert when its fair value changes →

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Explore undervalued stocks

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.